Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery

Abstract excerpt

Depriving cancer cells of sufficient NAD levels, mainly through interfering with their NAD-producing capacity, has been conceived as a promising anti-cancer strategy. Numerous inhibitors of the NAD-producing enzyme, nicotinamide phosphoribosyltransferase (NAMPT), have been developed over the past two decades. However, their limited anti-cancer activity in clinical trials raised the possibility that cancer cells...

Topics

Join the communities discussing this publication.

• Biochemical and Molecular Research
• PARP inhibition in cancer therapy
• Sirtuins and Resveratrol in Medicine